Product Description
Mechanisms of Action: DR Antagonist,5-HT Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Belgium | Israel | South Africa | Spain | Switzerland | Taiwan | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Fundacion Progreso y Salud
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Schizophrenia
Phase 3: Schizophrenia|Psychotic Disorders
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| Discontinuation clinical trial in first episode of non-affective psychosis | P3 |
Terminated |
Schizophrenia |
2016-03-21 |
2022-03-13 |
Treatments |
|
| NONSTOP | P3 |
Unknown status |
Schizophrenia|Psychotic Disorders |
2015-11-01 |
2024-10-16 |
Primary Endpoints|Treatments |
|
| INTENSIFY SZ | P4 |
Recruiting |
Schizophrenia |
2026-06-30 |
2025-05-02 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
06/29/2023 |
PubMed |
A brief history of clozapine use in Taiwan. |
|
12/07/2022 |
PubMed |
Antipsychotics in the Treatment of Children and Adolescents with Anorexia Nervosa: A Systematic Review. |